Ehtesham Abdi

3.3k total citations · 1 hit paper
43 papers, 1.4k citations indexed

About

Ehtesham Abdi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ehtesham Abdi has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Ehtesham Abdi's work include Cancer Treatment and Pharmacology (8 papers), Cancer survivorship and care (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ehtesham Abdi is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer survivorship and care (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Ehtesham Abdi collaborates with scholars based in Australia, Canada and United States. Ehtesham Abdi's co-authors include F. Yunus, R. Bell, Erhard Quebe‐Fehling, Glenn Mills, J.J. Body, Pierre Major, Alain Lortholary, Jeremy K. Hon, John J. Seaman and Gia‐Khanh Nguyen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ehtesham Abdi

41 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials

2001 520 citations Ehtesham Abdi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ehtesham Abdi Australia	18	907	436	205	169	161	43	1.4k
Steven A. Kuross United States	15	786 0.9×	368 0.8×	102 0.5×	177 1.0×	195 1.2×	19	1.4k
Tracey L. O’Connor United States	17	944 1.0×	332 0.8×	74 0.4×	121 0.7×	195 1.2×	59	1.4k
Rajesh Bandekar United States	19	405 0.4×	377 0.9×	69 0.3×	133 0.8×	262 1.6×	48	1.3k
Rohini K. Hernandez United States	21	587 0.6×	354 0.8×	91 0.4×	181 1.1×	187 1.2×	67	1.7k
Narhari Timilshina Canada	24	675 0.7×	978 2.2×	50 0.2×	82 0.5×	253 1.6×	97	1.8k
Francesco Bertoldo Italy	33	876 1.0×	252 0.6×	1.2k 5.8×	101 0.6×	542 3.4×	90	2.6k
Alessandro Giollo Italy	21	240 0.3×	266 0.6×	280 1.4×	81 0.5×	252 1.6×	90	1.5k
Richard Brasington United States	22	146 0.2×	398 0.9×	100 0.5×	76 0.4×	158 1.0×	41	1.7k
G. Albrand France	16	498 0.5×	389 0.9×	202 1.0×	70 0.4×	100 0.6×	44	1.5k
Wendy Ying United States	14	319 0.4×	147 0.3×	64 0.3×	115 0.7×	135 0.8×	26	987

Countries citing papers authored by Ehtesham Abdi

Since Specialization

Citations

This map shows the geographic impact of Ehtesham Abdi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ehtesham Abdi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ehtesham Abdi more than expected).

Fields of papers citing papers by Ehtesham Abdi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ehtesham Abdi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ehtesham Abdi. The network helps show where Ehtesham Abdi may publish in the future.

Co-authorship network of co-authors of Ehtesham Abdi

This figure shows the co-authorship network connecting the top 25 collaborators of Ehtesham Abdi. A scholar is included among the top collaborators of Ehtesham Abdi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ehtesham Abdi. Ehtesham Abdi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirby, Adrienne, Martin R. Stockler, Annette Tognela, et al.. (2023). Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.. Journal of Clinical Oncology. 41(16_suppl). 12019–12019. 5 indexed citations

Goel, Shom, Jia Liu, Hao Guo, et al.. (2019). Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Failure. 7(9). 795–804. 30 indexed citations

Regan, Meredith M., Barbara Walley, Prudence A. Francis, et al.. (2017). Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Annals of Oncology. 28(9). 2225–2232. 47 indexed citations

McCarthy, Nicole, Frances Boyle, Nicholas Zdenkowski, et al.. (2014). Neoadjuvant chemotherapy with sequential anthracycline–docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast. 23(2). 142–151. 5 indexed citations

Hertzberg, Mark, Jane Matthews, Janey M. Stone, et al.. (2014). A phase III randomized trial of high‐dose CEOP + filgrastim versus standard‐dose CEOP in patients with non‐Hodgkin lymphoma: 10‐year follow‐up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. American Journal of Hematology. 89(5). 536–541. 8 indexed citations

Hovey, Elizabeth, Paul de Souza, Gavin Marx, et al.. (2013). Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Supportive Care in Cancer. 22(5). 1233–1242. 27 indexed citations

Lomax, Anna J., Karen White, Jane Beith, et al.. (2013). Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial. Journal of bone oncology. 2(4). 145–153. 19 indexed citations

Murphy, Felicity, Diana Zannino, Kate Wilson, et al.. (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology. 22(8). 1834–1838. 38 indexed citations

Goldstein, David, M. Corona Gainford, Chris Brown, et al.. (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology. 67(3). 519–525. 10 indexed citations

10.

Kefford, Richard, Pippa Corrie, Ehtesham Abdi, et al.. (2009). A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. British Journal of Cancer. 100(8). 1245–1249. 21 indexed citations

11.

Stockler, Martin R., Rachel O’Connell, Anna K. Nowak, et al.. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology. 8(7). 603–612. 115 indexed citations

12.

Smith, Callum, Ehtesham Abdi, Michael F. Leahy, et al.. (2004). A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia & lymphoma. 46(2). 197–206. 11 indexed citations

13.

Wolf, M., JP Matthews, J. Stone, et al.. (2000). Dose-intensification does not improve outcome in aggressive non-Hodgkin's lymphoma (NHL). Report of a randomized trial by the Australasian Leukemia and Lymphoma Group (ALLG).. Blood. 96(11). 2 indexed citations

14.

Beller, Elaine, Martin Tattersall, Thomas Lumley, et al.. (1997). Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial. Annals of Oncology. 8(3). 277–283. 63 indexed citations

15.

Olweny, Charles L. M., Christopher A. Juttner, G. I. Barrow, et al.. (1993). Long-term effects of cancer treatment and consequences of cure: Cancer survivors enjoy quality of life similar to their neighbours. European Journal of Cancer. 29(6). 826–830. 24 indexed citations

16.

Abdi, Ehtesham, et al.. (1989). Adjuvant chemoimmuno‐ and immunotherapy in Dukes' stage B₂ and C colorectal carcinoma: A 7‐year follow‐up analysis. Journal of Surgical Oncology. 40(3). 205–213. 7 indexed citations

17.

Abdi, Ehtesham. (1988). Combination of interferon and prednisone in human cancer. European Journal of Cancer and Clinical Oncology. 24(4). 723–724. 6 indexed citations

18.

Abdi, Ehtesham, et al.. (1988). The syndrome of inappropriate antidiuretic hormone secretion with carcinoma of the tongue. Medical and Pediatric Oncology. 16(3). 210–215. 9 indexed citations

19.

Abdi, Ehtesham, Yadi Tan, & T. A. McPherson. (1988). Natural Human Interferon-Beta in Metastatic Malignant Melanoma: A phase II study. Acta Oncologica. 27(6). 815–817. 9 indexed citations

20.

Abdi, Ehtesham, et al.. (1987). An unusual case of renal cancer showing mixed tumor response to interferon. The American Journal of Medicine. 83(6). 1147–1150. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact